Bacterial Vaginosis Drugs Market

SKU: DMPH2857 | Last Updated On: Oct 07 2022 | Available Formats

>Bacterial Vaginosis Drugs Market Expected to reach a high CAGR during the forecast period 2022-2029: DataM Intelligence

Bacterial Vaginosis Drugs Market is segmented By Drug (Metronidazole (Flagyl, Metrogel-Vaginal, others), Clindamycin (Cleocin, Clindesse, others), Tinidazole (Tindamax), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Bacterial Vaginosis Drugs Market was valued at USD 958.75 Million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 2,5% during the forecast period (2022-2029).

Vitamin D Therapy Market

Metrics

Details

Market CAGR

2.5%

Segments Covered

By Drug, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Bacterial Vaginosis (BV), also referred to as non-specific vaginitis, is a vaginal disorder that produces vaginal discharge due to an overgrowth of certain kinds of bacteria in the vagina. Previously, the condition was named Gardnerella vaginitis, after the bacteria that were thought to cause the condition. However, now it is called bacterial vaginosis, which reflects the fact that several species of bacteria naturally live in the vaginal area and may grow to excess, rather than an actual infection with foreign bacteria, such as occurs with many sexually-transmitted diseases (STDs).

Bacterial vaginosis is more commonly associated with vulvovaginal symptoms such as itching, discharge, odour, and discomfort. As per the Centers for Disease Control and Prevention (CDC), more than 84% of women suffering from bacterial vaginosis have no symptoms. It is a common disorder of the genital tract among women of reproductive age and the prevalent cause of vaginal discharge and malodor. Bacterial vaginosis may lead to several gynecologic and obstetric complications such as preterm premature rupture of membranes (preterm PROM), preterm delivery and labour, spontaneous abortion, postpartum endometritis, postsurgical infections, post-cesarean-delivery wound infections, and subclinical pelvic inflammatory disease.

Some symptoms of bacterial vaginosis include an abnormal amount of vaginal discharge, thin and greyish white vaginal discharge and vaginal odor. Certain risk factors have also been identified that increase the chances of developing Bacterial Vaginosis. These risk factors for BV include antibiotic use, intrauterine devices for birth control, and cigarette smoking.

Bacterial vaginosis is diagnosed by a vaginal swab test, and the treatment for bacterial vaginosis can be done by using antibiotics, vaginal gels and creams, which can change the acidity of the vagina.

Market Dynamics

The global bacterial vaginosis drugs market growth is driven by factors such as the rising incidence of bacterial vaginosis, growing awareness towards women health, and increasing development of drugs for the treatment.

The increasing incidence of bacterial vaginosis is driving the market growth.

As per the American Sexual Health Association, BV is a common gynecologic infection, affecting nearly 29% of women in the US. As per the study by David A. Eschenbach et al. (2007), BV is one of the most common infections among sexually active women that is responsive to antibiotics. BV is present in at least 15% of the sexually active population; this makes BV 3–4 times more common than urinary tract infections.

The United States has the highest percentage of prevalent diagnosed and treated patients of BV among the 7MM.

Hence, the increasing incidence of bacterial vaginosis is leading to a rise in research and development for its treatment by private manufacturers and research organizations. Several clinical trials are undergoing to expand the potential future of Bacterial Vaginosis drugs.

Epidemiology

United States: Bacterial Vaginosis (BV) occurs in one-third of adult women in the United States, around 21 million women. Women make around 10 million office visits for vaginal discharge every year. The rising prevalence is associated with cigarette smoking, obesity, being single/never married, before pregnancy, and a history of induced abortion.

Gardnerella vaginalis occurs in up to 100% of women with signs and symptoms of bacterial vaginosis and up to 70% of women with no signs or symptoms of bacterial vaginosis. G. vaginalis has been isolated in up to 80% of the urethras of male sexual partners of women with bacterial vaginosis.

The incidence of bacterial vaginosis in patients attending obstetric clinics is around 10-25% and as high as 30-65% in patients attending sexually transmitted disease clinics.

Some studies have shown that bacterial vaginosis occurs more commonly among African American women than non-Hispanic white women.

G. vaginalis infections commonly occur in women of reproductive age. As per some studies, G. vaginalis colonization in prepubertal and virginal girls and boys and cases of bacterial vaginosis occurring in prepubertal and virginal girls.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global bacterial vaginosis drugs market impacts growth from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by COVID-19.

 Segment Analysis

By Drugs type Metronidazole is expected to hold a significant market share

Antibiotics are one of the major treatments for bacterial vaginosis. Some of the medications include Metronidazole (Flagyl), clindamycin (Cleocin), oral or vaginal suppositories, and metronidazole vaginal gel (MetroGel-Vaginal), among others. Metronidazole and clindamycin are mostly preferred to treat Gardnerella infections.

In February 2022, the FDA approved secnidazole for treating bacterial vaginosis and trichomoniasis in patients aged 12.

In addition, on 9th December, 2021, The FDA also approved the new drug application (NDA) for clindamycin phosphate vaginal gel, formerly known as DARE-BV, for treating bacterial vaginosis in females 12 years and older.

Some of the drugs used for the treatment of BV include:

Clindamycin (Cleocin): Bacteriostatic antibiotic is against gram-positive aerobes and gram-positive and gram-negative anaerobes. It inhibits bacterial growth, possibly by blocking the dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It is available as a capsule and 2% vaginal cream formulation.

Metronidazole (Flagyl, MetroGel-Vaginal)): Bactericidal antibiotic enters the bacterial cell and is reduced by electron transport proteins. The free radicals are formed, which react with intracellular components and/or DNA and result in subsequent cell death. The antimicrobial spectrum includes many gram-positive and gram-negative anaerobes and protozoal parasites.

Secnidazole (Solosec): Secnidazole is a nitroimidazole derivative; 5-nitroimidazoles enter the bacterial cell as an inactive prodrug where enzymes reduce the nitro group to radical anions. These radical anions interfere with the bacterial DNA synthesis of susceptible isolates.

Geographical Analysis

North America is dominating the global Bacterial Vaginosis drugs market

The Asia Pacific BV market is anticipated to grow fastest over the forecast period (2022-2027). A high percentage of people belonging to the sexually active age group in developing countries such as India and China is expected to the growing demand for vaginal drugs in the Asia Pacific shortly. As per the Index Mundi, a data portal that gathers facts and statistics, over 16 crore women in China belonged to the age group of 15–24 years, while more than ten crore women belonged to the age group of 25–54 years, as of September 2021. The Index Mundi statistics also revealed that more than 108.7 million women in India come under the age group of 15–25 years while more than 265.84 million women belong to the age group of 25–54 years. The large presence base of sexually active women susceptible to bacterial vaginosis is expected to grow the market for bacterial vaginosis treatment in Asia-Pacific during the forecast period.

North America accounted for the largest market share in 2021 bacterial vaginosis, owing to high awareness among women towards bacterial vaginosis and its treatment, growing prevalence of the disorder, and rising disposable income. As per the data from the CDC, the prevalence of bacterial vaginosis in the United States is estimated to be around 21.2 million (29.2%) in women aged 14–49 years.

On the other hand, the Middle East & Africa and South America regions are expected to be prospective markets for bacterial vaginosis treatment over the forecast period, owing to the rising prevalence of bacterial vaginosis, growing awareness of the disease and its treatment among women, increasing disposable income, and highly developing health care industry in these regions.

Competitive Landscape:

Some of the major players in the bacterial vaginosis treatment market include Bayer, Pfizer, Sanofi, Starpharma Holdings, Allergan, AstraZeneca, Cardinal Health, Mylan, Novartis, Sun Pharmaceutical Industries, Symbiomix Therapeutics, and Teva Pharmaceutical Industries.

These companies offer various products, which are being used for the treatment of BV. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the bacterial vaginosis drugs market globally.

On August 20th 2020, Daré Bioscience, Inc., a leader in women’s health innovation, announced the publication of a proof-of-concept study of DARE-BV1 in Clinical and Experimental Obstetrics & Gynecology, an international journal focused on the publication of high-quality scientific research related to obstetrics and gynaecology and women’s health. DARE-BV1 is a novel thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% that is being evaluated as a one-time vaginally administered treatment for bacterial vaginosis (BV).

Bayer AG

Overview:

Bayer AG is a German multinational pharmaceutical and life sciences company headquartered in Leverkusen. Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds and biotechnology products. The Pharmaceuticals Division focuses on prescription products, especially for women's healthcare and cardiology, and also on speciality therapeutics in the areas of oncology, haematology and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.

Product Portfolio:

CanesBalance Bacterial Vaginosis (BV) Vaginal Gel: CanesBalance BV Gel Triple Benefit Formula is an effective 7-day treatment that relieves the symptoms of BV infection. CanesBalance works by its effect on the vaginal pH which effectively relieves unpleasant odour and abnormal vaginal discharge.

Trending Topics

Drug Discovery Informatics Market

Biological API Drug Manufacturing Market

Anti-Hypertension Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest